Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Common Equity (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Common Equity for 4 consecutive years, with $42.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 47.52% to $42.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.5 million through Dec 2025, up 47.52% year-over-year, with the annual reading at $42.5 million for FY2025, 47.52% up from the prior year.
  • Common Equity for Q4 2025 was $42.5 million at Spruce Biosciences, up from $5.4 million in the prior quarter.
  • The five-year high for Common Equity was $108.0 million in Q1 2023, with the low at $5.4 million in Q3 2025.
  • Average Common Equity over 4 years is $61.6 million, with a median of $67.6 million recorded in 2022.
  • Peak annual rise in Common Equity hit 47.52% in 2025, while the deepest fall reached 89.57% in 2025.
  • Over 4 years, Common Equity stood at $68.5 million in 2022, then increased by 11.71% to $76.5 million in 2023, then plummeted by 62.33% to $28.8 million in 2024, then soared by 47.52% to $42.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $42.5 million, $5.4 million, and $13.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.